Barclays
ASPN icon

Barclays’s Aspen Aerogels ASPN Stock Holding History

Barclays’s Portfolio ASPN Stock Details ASPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-83,400
Closed -$236K – 5041
2025
Q4 		$236K Buy
+83,400
New +$430K ﹤0.01% 4228

Other funds holding ASPN

KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
OCMI
Oaktop Capital Management II Chatham, New Jersey $1.34B AUM 114.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GKFF
George Kaiser Family Foundation Tulsa, Oklahoma $883M AUM 21.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Barclays's ASPN Position: Q1 2026 in Review

Barclays reduced its Aspen Aerogels (ASPN) stake by 83% in Q1 2026, selling an estimated $307K and leaving 18,447 shares worth $63.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4225.

Barclays first reported a position in ASPN in Q2 2014 and has held it in 34 quarters since. The position peaked at $11.9M in Q2 2014. 166 funds tracked by Wall St. Rank hold ASPN as of Q1 2026.

  • Barclays held 18,447 shares of Aspen Aerogels worth $63.1K as of Q1 2026.
  • Barclays sold 91,081 Aspen Aerogels shares in Q1 2026, an estimated $307K.
  • Aspen Aerogels made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4225 holding.
  • Barclays first reported a position in Aspen Aerogels in Q2 2014 and has held it in 34 quarters since.
  • Barclays's Aspen Aerogels position peaked at $11.9M in Q2 2014.
  • 166 funds tracked by Wall St. Rank held Aspen Aerogels as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.